BBOT

BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT

Overview Fund Activity

29 hedge funds and large institutions have $167M invested in BridgeBio Oncology Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 29 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
29
Holders Change
+29
Holders Change %
–
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
CAM
1
Cormorant Asset Management
Massachusetts
$30.3M
2
BlackRock
2
BlackRock
New York
$15.6M
3
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$14.6M
4
Citadel Advisors
4
Citadel Advisors
Florida
$13.8M
5
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$11.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Shares
Change %
CAC
26
Cowen and Company
New York
$566K +$566K +54,413 New
Walleye Trading
27
Walleye Trading
New York
$537K +$537K +51,876 New
Geode Capital Management
28
Geode Capital Management
Massachusetts
$112K +$112K +10,869 New
JPMorgan Chase & Co
29
JPMorgan Chase & Co
New York
$41 +$41 +4 New
1
2